病例报告：单倍体异基因干细胞移植后淋巴增殖性疾病患者接受嵌合抗原受体T细胞疗法取得成功
Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients With Post-Transplant Lymphoproliferative Disorder.
作者信息
Yan Nan, Wang Na, Zhang Peiling, Wang Gaoxiang, Mao Xia, Peng Dan, Kuang Dong, Chen Liting, Zhu Li, Zhou Jianfeng, Zhang Yicheng, Cao Yang
机构信息
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China.
出版信息
Front Oncol. 2021 Jul 22;11:709370. doi: 10.3389/fonc.2021.709370. eCollection 2021.
BACKGROUND
Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV-PTLD) is a potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Rituximab has been proven to dramatically improve the prognosis of patients with EBV reactivation and PTLD. However, reports on the curative management of refractory PTLD are scarce.
CASE PRESENTATION
In this report, we describe the successful management of two patients with EBV-PTLD with chimeric antigen receptor T-cell (CAR-T) therapy.
CONCLUSION
The present results demonstrated that patients with EBV-PTLD may benefit from CAR-T therapy and that the toxicity is manageable. Further studies are needed to verify these findings.
背景
爱泼斯坦-巴尔病毒相关的移植后淋巴细胞增殖性疾病（EBV-PTLD）是异基因造血干细胞移植（allo-HSCT）后一种潜在的致命并发症。利妥昔单抗已被证明能显著改善EBV激活和PTLD患者的预后。然而，关于难治性PTLD治疗管理的报道很少。
病例报告
在本报告中，我们描述了通过嵌合抗原受体T细胞（CAR-T）疗法成功治疗两名EBV-PTLD患者的情况。
结论
目前的结果表明，EBV-PTLD患者可能从CAR-T疗法中获益，且毒性是可控的。需要进一步研究来验证这些发现。
Zotero 插件